Pliant Therapeutics Inc (NAS:PLRX)
$ 12.93 -0.47 (-3.51%) Market Cap: 780.01 Mil Enterprise Value: 376.36 Mil PE Ratio: 0 PB Ratio: 1.78 GF Score: 36/100

Pliant Therapeutics Inc at Cantor Fitzgerald Global Healthcare Conference Transcript

Sep 28, 2023 / 03:30PM GMT
Release Date Price: $16.4 (-0.97%)
Pete Stavropoulos
Cantor Fitzgerald - Analyst

The Cantor Global Healthcare Conference. I'm Pete Stavropoulos, biotech analyst at Cantor. With us, we have Pliant Therapeutics, a company I cover. And I'm pleased to introduce Bernard Coulie, President and CEO; and Ãric Lefebvre, CMO.

Welcome to the conference. Let's start off with a bit of an overview of Pliant, the company -- for those who are not familiar with the company.

Bernard Coulie
Pliant Therapeutics, Inc. - President and CEO

Absolutely. And thanks, Pete, for having us here at the Cantor conference. Pliant Therapeutics started about seven years ago with a mission and a focus on developing novel therapeutics for fibrotic diseases. To that end, we have built a platform that is addressing integrins, which are known to activate TGF-β, which is the main driver of fibrosis. And by blocking those integrins, we basically block the TGF-β pathway, thereby blocking propagation -- initiation and propagation of fibrosis. So out of that platform, it's a small molecule library, basically unmatched in the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot